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Objective. The aim of the present study was to investigate the usefulness of the CA-125 area under the curve (AUC) as a new kinetic
parameter for predicting overall survival in patients with ovarian cancer. In addition, the relationship of CA-125 AUC with other prognostic
factors of ovarian cancer was evaluated.
Methods. Ninety-two patients that underwent primary line chemotherapy within 4 months after submission to cytoreductive surgery were
included. For each patient, CA-125 AUC was calculated and a statistical analysis was conducted to compare CA-125 AUC behavior among
patients according to several covariates.
Results. The mean age at diagnostic time was found to be 55.5 (16.1–82.4) years with a mean survival of 39.2 (3.5–100.1; SE = 2.6)
months. Across FIGO stage I, II, III, and IV patients had a mean CA-125 AUC of 18.2, 24.6, 147.8, and 574.6 IU/ml*days, respectively (P b
0.05). At the evaluation date, living patients had a mean CA-125 AUC of 40.1 in contrast to 234.1 IU/ml*days (P b 0.05) for deceased ones.
Patients with a complete response to primary chemotherapy had a mean CA-125 AUC of 48.8, while patients with a partial response had a
mean of 251.7 IU/ml*days, and patients with no response or disease progression had a mean of 316.5 IU/ml*days (P b 0.05). The best CA-
125 AUC performance is in predicting patient complete response to chemotherapy with a cut-off of 100 IU/ml*days and an accuracy of 82%.
Conclusions. Despite CA-125 AUC high correlation with the FIGO stage, residual disease, and patient final outcome, the main interest of
CA-125 AUC calculation is to evaluate the treatment efficacy and to foresee a full chemotherapy response. Further studies should be carried
out before extrapolating these results to other data sets.
D 2005 Elsevier Inc. All rights reserved.
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Ovarian cancer, generally treated with combination first
line chemotherapy after cytoreduction surgery [1,2], has the
highest mortality rate of all invasive cancers of the
gynecological system. Bast et al. [3] first described a
radioimmunoassay that could detect CA-125 (Cancer
Antigen 125) in the serum of ovarian cancer patients [3].
CA-125 serum concentration is usually adopted to evaluate
the clinical situation in ovarian cancer patients and the rate
of decline in CA-125 during primary chemotherapy has0090-8258/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygyno.2005.01.040
T Corresponding author. Fax: +351 239855099.
E-mail address: acfalcao@ff.uc.pt (A. Falca˜o).been an important prognostic factor in several multivariate
analyses [4]. The postoperative serum CA-125 level is an
independent prognostic factor in patients with invasive
ovarian cancer [5], and CA-125 tumor marker half-life (t1/2)
and tumor marker doubling time (DT) are often used as
kinetic parameters for the evaluation of clinical response
and follow-up of patients with ovarian cancer [6]. Serum
CA-125 half-life during early chemotherapy is an inde-
pendent prognostic factor for both the achievement of a
pathologically complete response and the survival of
patients with advanced epithelial ovarian cancer [7], and
several studies report that the greatest difference in
progression rate was found at a t1/2 of 20 days [8–11].
Nevertheless, although CA-125 level before the 3rd course
of chemotherapy was considered the best prognostic97 (2005) 529–534
A. Mano et al. / Gynecologic Oncology 97 (2005) 529–534530indicator by Fayers et al., it was classified inaccurately for
clinical use [12].
In addition to CA-125 kinetic parameters, several other
prognostic factors can be used in the management of ovarian
cancer: the FIGO (Fe´de´ration Internationale de Gyne´cologie
et d’Obstre´trique) tumor stage, tumor grade, tumor biology,
overexpression of the HER-2/neu oncogene, residual
disease after initial cytoreductive surgery, and rate of
response to chemotherapy [13].
CA-125 tumor marker kinetics are more important than
the isolated value of CA-125 serum concentration for
patient prognosis, and in the present work, we propose a
new kinetic parameter: the CA-125 area under the curve
(AUC) and its relation with the FIGO stage, patient final
state, tumor grade, residual disease, and primary chemo-
therapy response. Additionally, the influence of this newFig. 1. CA-125 AUC hypothetical determination in a patient with ovarian cancer
with an optimal CA-125 serum levels evolution during treatment; (B) patient witprognostic factor to overall survival in patients with ovarian
cancer was also studied in our population.Patients and methods
Retrospective clinical information was gathered from
339 patients with a diagnosis of ovarian cancer at the
Gynaecology Service of Coimbra University Hospital
(CUH) main database from 1990 to 2000. In addition,
CA-125 serum levels of these patients were obtained from
the Pathology Service (Hormonology and Drug Monitoring
Laboratory) of CUH. Only 92 patients were included in the
present analysis due to the restriction of our inclusion
criteria: patients that underwent primary line chemotherapy
within 4 months after submission to cytoreductive surgerytreated with first line chemotherapy after cytoreductive surgery; (A) patient
h an unstable CA-125 serum levels during treatment.
Table 1
Summary of patient characteristics
Patient count (%)
FIGO stage
I 19 (20.7)
II 11 (11.9)
III 51 (55.4)
IV 9 (9.8)
Missing 2 (2.2)
Patient final state
Deceased 50 (54.3)
Alive 42 (45.7)
Tumor grade
1 12 (13.0)
2 29 (31.5)
3 9 (9.8)
Missing 42 (45.7)
Histological type
Epithelial 82 (89.1)
Other 8 (8.7)
Missing 2 (2.2)
Residual disease ( N2 cm)
Yes 36 (39.1)
No 53 (57.6)
Missing 3 (3.3)
Primary chemotherapy response
Complete response (CR) 52 (56.5)
Partial response (PR) 22 (23.9)
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between the time of surgery and the end of chemotherapy.
For each patient, CA-125 AUC was calculated using the
following formula:
CA125AUC¼ðsum of all trapezoid are as between C1 and C2Þ= t2  t1Þð
where C1 is the first CA-125 serum concentration after the
cytoreduction surgery and C2 is the last CA-125 serum
concentration before the end of first line chemotherapy, and
t1 and t2 are the corresponding dates for C1 and C2,
respectively (Fig. 1). A statistical analysis was conducted.
The Mann–Whitney U test (for two groups) and Kruskal–
Wallis test (for three or more groups) were used to compare
the CA-125 AUC across subgroups of patients, depending
on the FIGO stage, patient final state, tumor grade,
histological type, residual disease (N2 cm), and response to
primary chemotherapy. The area under the Receiver Operat-
ing Characteristic (ROC) curve was established for the
discrimination by CA-125 AUC in predicting the patient
final state, overall survival equal or superior to 1, 3, and 5
years, and a full response to chemotherapy. Sensitivity,
specificity, positive predictive values (PPV), and overall
accuracy were also determined for several CA-125 AUC cut-
offs. In addition, a multivariant regression analysis based on
the Cox proportional hazard model to test the variation of
CA-125 AUC in relation to the overall survival time was
also carried out. A P levelV0.05 was considered significant.
Without response or disease progression (WR/DP) 13 (14.1)
Missing 5 (5.4)
Overall survival
z1 year 80 (86.9)
z3 years 44 (47.8)
z5 years 21 (22.8)Results
The mean age at diagnostic time was found to be 55.5
(16.1–82.4; SE = 1.65) years with a mean overall survival of
39.2 (3.5–100.1; SE = 2.6) months. According to the FIGO
tumor stage, nineteen (20.7%) patients had stage I, eleven
(11.9%) had stage II, fifty-one (55.4%) had stage III, nine
(9.8%) had stage IV, and in two (2.2%) patients this
information was missing. Eighty-two (89.1%) patients had
epithelial ovarian cancer for histological type. Twelve
(13.0%) patients had a tumor grade 1, twenty-nine
(31.5%) a tumor grade 2, nine (9.8%) had a tumor grade
3, and forty-two (45.7%) patients had no tumor grade
information. Thirty-six (39.1%) patients had a residual
tumor greater than 2 cm after surgery. The mean duration
of primary chemotherapy was 4.1 (0.7–10.2; SE = 0.15)
months: fifty-two (56.5%) patients had a complete response
to primary chemotherapy, twenty-two (23.9%) had a partial
response, thirteen (14.1%) had no response or a disease
progression, and five (5.4%) patients had missing informa-
tion for the response to chemotherapy. At evaluation date,
fifty (54.3%) patients were deceased while forty-two
(45.7%) were alive. Eighty patients (86.9%) had at least 1
year survival, forty-four (47.8%) had at least 3 years while
only twenty-one (22.8%) had more than 5 years survival
(Table 1).The CA-125 AUC across groups of patients is shown in
Table 2. Patients with FIGO stage I, II, III, and IV had a
mean CA-125 AUC of 18.2 (SE = 2.4) IU/ml*days, 24.6
(SE = 7.6) IU/ml*days, 147.8 (SE = 30.8) IU/ml*days, and
574.6 (SE = 134.6) IU/ml*days, respectively (P b 0.05)
(Fig. 2). Patients with a tumor grade 1, 2, and 3 had a mean
CA-125 AUC of 100.1 (45.5) IU/ml*days, 158.1 (43.0) IU/
ml*days, and 238.8 (114.0) IU/ml*days, respectively (P N
0.05). Patients with residual disease (N2 cm) had a mean
CA-125 AUC of 207.4 (SE = 48.3) IU/ml*days, while
patients without residual disease had 97.9 (SE = 30.0) IU/
ml*days (P b 0.05). At the evaluation date, living patients
had a mean CA-125 AUC of 40.1 (SE = 10.5) IU/ml*days
in contrast to deceased patients, who had a CA-125 AUC of
234.1 (SE = 44.4) IU/ml*days (P b 0.05). Fifty-two patients
had a complete response to primary chemotherapy with a
mean CA-125 AUC of 48.8 IU/ml*days (SE = 15.9) while
twenty-two patients had a partial response and thirteen
patients had no response or disease progression with a mean
CA-125 AUC of 251.7 IU/ml*days (SE = 65.8) and a mean
Fig. 3. CA-125 mean plot according to patient response to primary
chemotherapy. (CR = complete response; PR = partial response; WRDP =
without response or disease progression.)
Table 2
CA-125 AUC behavior among patients according to several covariates
Group Mean CA-125
AUC
(standard error)
[IU/ml*days]
Median CA-125
AUC (Q25–Q75)
[IU/ml*days]
P value
FIGO stage
I 18.2 (2.4) 14.6 (12.0–20.1) P b 0.05
II 24.6 (7.6) 14.4 (9.8–20.5)
III 147.8 (30.8) 54.2 (23.5–199.5)
IV 574.6 (134.6) 676.3 (118.6–973.3)
Patient final state
Deceased 234.1 (44.4) 83.2 (23.5–319.5) P b 0.05
Alive 40.1 (10.5) 16.5 (12.0–34.0)
Tumor grade
1 100.1 (45.5) 19.8 (12.3–146.9) NS
2 158.1 (43.0) 65.8 (16.6–230.7)
3 238.8 (114.0) 44.8 (37.3–375.2)
Residual disease ( N2 cm)
Yes 207.4 (48.3) 98.1 (31.3–237.9) P b 0.05
No 97.9 (30.0) 16.6 (12.0–44.8)
Primary chemotherapy response
Complete response (CR) 48.8 (15.9) 16.8 (12.0–34.1) P b 0.05
Partial response (PR) 251.7 (65.8) 98.1 (51.9–319.5)
Without response or
disease progression
(WR/DP)
316.5 (107.5) 116.8 (54.2–344.3)
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(Fig. 3).
For predicting the patient final state, the best accuracy
(74%) was achieved at CA-125 AUC V 100 IU/ml*days
(ROC AUC = 0.77). To predict patient survival, the most
accurate was 87% (CA-125 AUC V 1000 IU/ml*days),
72% (CA-125 AUC V 100 IU/ml*days), and 66% (CA-125
AUC V 25 IU/ml*days) for a 1-, 3-, and 5-year overall
survival, respectively (ROC AUC = 0.67, 0.75, and 0.73). In
predicting a complete response to chemotherapy (ROC
AUC = 0.87), the best CA-125 AUC cut-off was 100 IU/Fig. 2. CA-125 mean plot according to patients’ FIGO tumor stage.ml*days with an accuracy of 82% (Table 3). We estimated
the parameters in the Cox proportional hazard model using
overall survival as a dependent variable, CA-125 AUC as an
independent variable, and the patient final state (bAliveQ or
bDeceasedQ) as a censoring variable. FIGO tumor stage,
residual disease, and primary chemotherapy response were
stratification variables (Table 4). Fig. 4 shows the survival
functions for different values of CA-125 AUC produced
with the Cox model without any stratification variable.Discussion
Many authors have studied the CA-125 kinetic in
monitoring the ovarian cancer patient. Kinetic parameters
prove to be more useful than rough serum concentration
alone. Van der Burg et al. [8], Hawkins et al. [9], Verda et al.
[10], S. E`olakovi& et al. [11], and others used the CA-125
half-life value to evaluate patient survival, finding a t1/2 of
20 days to be a breakpoint between a bgoodQ and bpoorQ
prognosis.
Buller et al. showed that the rate of decline of CA-125 in
effectively treated ovarian cancer is described by an
exponential model and his study suggests that it is possible
to predict overall survival, which patients have residual
disease at reassessment laparotomy, who will be free of
disease, and who will have a recurrence [14,15].
In a review article, Jean-Michel et al. [6] accentuated the
value of different serum marker kinetic parameters in the
monitoring of patients in several types of cancer.
To increase the value of CA-125 kinetics as a prognostic
factor in ovarian cancer, we proposed and studied a new
kinetic parameter: CA-125 AUC. As can be seen in Figs.
1A/B, the CA-125 AUC calculation is independent of the
shape presented by the CA-125 serum concentrations,
making CA-125 AUC a more suitable kinetic parameter
than CA-125 half-life (Fig. 1A). In addition, the CA-125
Table 3
Sensitivity, specificity, positive predictive value (PPV), and accuracy of several CA-125 AUC cut-offs for predicting the patient final state, overall survival, and
chemotherapy complete response (SE = standard error)
CA-125 AUC [IU/ml*days] V25 V50 V100 V200 V300 V400 V500 V600 V800 V1000 ROC AUC (SE)
CA-125 cut-off to predict patient final state baliveQ
Sensitivity 0.62 0.86 0.86 0.95 0.97 1.00 1.00 1.00 1.00 1.00 0.77 (0.05)
Specificity 0.72 0.64 0.64 0.32 0.30 0.20 0.20 0.14 0.08 0.04
PPV 0.65 0.67 0.67 0.54 0.54 0.51 0.51 0.50 0.48 0.47
Accuracy 0.67 0.74 0.74 0.61 0.61 0.57 0.57 0.53 0.50 0.48
CA-125 cut-off to predict patient overall survival z 1 year
Sensitivity 0.48 0.63 0.63 0.81 0.84 0.90 0.90 0.94 0.98 0.99 0.67 (0.08)
Specificity 0.83 0.67 0.67 0.25 0.25 0.17 0.17 0.17 0.17 0.08
PPV 0.95 0.93 0.93 0.88 0.88 0.88 0.88 0.88 0.89 0.88
Accuracy 0.52 0.63 0.63 0.74 0.76 0.80 0.80 0.84 0.87 0.87
CA-125 cut-off to predict patient overall survival z 3 years
Sensitivity 0.64 0.82 0.82 0.98 0.98 0.98 0.98 0.98 0.98 1.00 0.75 (0.05)
Specificity 0.75 0.63 0.63 0.35 0.31 0.19 0.19 0.13 0.06 0.04
PPV 0.70 0.67 0.67 0.58 0.57 0.52 0.52 0.51 0.49 0.49
Accuracy 0.70 0.72 0.72 0.65 0.63 0.57 0.57 0.53 0.50 0.50
CA-125 cut-off to predict patient overall survival z 5 years
Sensitivity 0.71 0.90 0.90 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.73 (0.06)
Specificity 0.65 0.51 0.51 0.25 0.23 0.14 0.14 0.10 0.08 0.04
PPV 0.38 0.35 0.35 0.28 0.28 0.26 0.26 0.25 0.44 0.43
Accuracy 0.66 0.60 0.60 0.42 0.40 0.34 0.34 0.30 0.47 0.45
CA-125 cut-off to predict patient complete response to chemotherapy
Sensitivity 0.65 0.85 0.85 0.94 0.96 0.98 0.98 0.98 1.00 1.00 0.87 (0.04)
Specificity 0.89 0.77 0.77 0.37 0.34 0.23 0.23 0.14 0.11 0.06
PPV 0.89 0.85 0.85 0.69 0.68 0.65 0.65 0.63 0.63 0.61
Accuracy 0.75 0.82 0.82 0.71 0.71 0.68 0.68 0.64 0.64 0.62
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surgery) and sources of variability (i.e., intra-subject and
assay variability).
In the present work, the poor correlation between CA-
125 AUC and tumor grade is perhaps the consequence of
the high number of patients without this information.
Inversely, CA-125 AUC is highly correlated with the FIGO
stage in which lower values are related with stage I and II,
middle values with stage III, and higher values with stage
IV. Patients with stage IV have a mean CA-125 AUC 31.6
times greater than patients with stage I. CA-125 AUC is also
correlated with residual disease for patients with a residual
tumor N2 cm after initial cytoreductive surgery (mean CA-
125 AUC 2.1 times greater). CA-125 AUC is also correlated
with patient final state in deceased patients, having a meanTable 4
Cox proportional hazard model results for CA-125 AUC as an independent
factor for predicting patient overall survival
Dependent: overall survival; independent: CA-125 AUC; censoring
variable: patient final state (deceased/alive)
Stratified by: Chi-square P value
None 18.19 P b 0.05
FIGO tumor stage (I, II, III, IV) 6.42 P b 0.05
Residual disease (N2 cm) 14.80 P b 0.05
Primary chemotherapy response
(CR, PR, WR/DP)
1.83 NSCA-125 AUC 5.8 times greater than living. As shown by the
Cox proportional hazard model, the CA-125 AUC is an
independent prognostic factor for patient overall survival
and patients with a lower CA-125 AUC have a better overall
survival than patients with a higher CA-125 AUC.
Concerning survival forecast, the best CA-125 AUC cut-
off was 100 IU/ml*days, obtained for predicting an overall
survival z3 years, the patient final state baliveQ, and the
complete response to chemotherapy, with an accuracy of
72%, 74%, and 82%, respectively. In fact, it seems clear thatFig. 4. Survival function for hypothetical CA-125 AUC values.
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response, while higher values are associated with a partial
response or even a disease progression. Therefore, CA-125
AUC could be a useful measure of the primary treatment
efficacy, not only to evaluate the cytoreductive surgery but
also the chemotherapy cocktail adopted. Regarding the CA-
125 AUC kinetic, the objective of initial treatment
(cytoreductive surgery and primary chemotherapy) of
ovarian cancer is to produce the lowest CA-125 AUC
possible. In addition, the CA-125 AUC kinetic parameter
could be useful as an end-point in the development of new
chemotherapy drugs or to establish new guidelines for the
primary treatment of ovarian cancer.
Finally, CA-125 AUC presents some benefits over other
kinetic parameters: it is easier to calculate and model-
independent. Nevertheless, further studies should be carried
out in order to compare CA-125 AUC with other prognostic
factors used in the management of ovarian cancer patients
and caution should be exercised before extrapolation of the
present results to different data sets.References
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